Rapid Antidepressant Effects and MADRS Item Improvements With AXS-05 (DEXTROMETHORPHAN-BUPROPION), an Oral NMDA Receptor Antagonist in Major Depressive Disorder: Results From Two Randomized Double-Blind, Controlled Trials

被引:1
|
作者
Jones, Amanda [1 ]
Streicher, Caroline [1 ]
Alter, Shawn [1 ]
Thomas, Zachariah [1 ]
Tabuteau, Herriot [1 ]
机构
[1] Axsome Therapeut, New York, NY USA
关键词
D O I
10.1017/S1092852923002158
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
引用
收藏
页码:263 / 263
页数:1
相关论文
共 20 条
  • [1] Rapid Antidepressant Effects and MADRS Core Symptom Improvements With AXS-05, an Oral NMDA Receptor Antagonist, in Major Depressive Disorder: Results From Two Randomized, Double-Blind, Controlled Trials
    O'Gorman, Cedric
    Jones, Amanda
    Anderson, Ashley
    Jacobson, Mark
    Feliz, Samantha
    Streicher, Caroline
    Thomas, Zachariah
    Tabuteau, Herriot
    [J]. NEUROPSYCHOPHARMACOLOGY, 2021, 46 (SUPPL 1) : 201 - 202
  • [2] Rapid Effects of AXS-05, an Oral NMDA Receptor Antagonist, in Major Depressive Disorder: Results From Two Randomized, Double-Blind, Controlled Trials
    O'Gorman, Cedric
    Jones, Amanda
    Iosifescu, Dan V.
    Thomas, Zachariah
    Tabuteau, Herriot
    [J]. BIOLOGICAL PSYCHIATRY, 2021, 89 (09) : S244 - S244
  • [3] Effect of AXS-05 (Dextromethorphan-Bupropion) in Major Depressive Disorder: A Randomized Double-Blind Controlled Trial
    Tabuteau, Herriot
    Jones, Amanda
    Anderson, Ashley
    Jacobson, Mark
    Iosifescu, Dan, V
    [J]. AMERICAN JOURNAL OF PSYCHIATRY, 2022, 179 (07): : 490 - 499
  • [4] Impact of AXS-05 (DEXTROMETHORPHAN-BUPROPION), an Oral NMDA Receptor Antagonist, on Anhedonic Symptoms in Major Depressive Disorder
    Jones, Amanda
    McIntyre, Roger S.
    Jacobsen, Mark
    Streicher, Caroline
    Thomas, Zachariah
    Tabuteau, Herriot
    [J]. CNS SPECTRUMS, 2023, 28 (02) : 264 - 264
  • [5] AXS-05 (dextromethorphan/bupropion), a novel, oral, investigational agent for major depressive disorder: Results of a randomized, double-blind, active-controlled, multi-center trial (ASCEND)
    O'gorman, C.
    Anderson, A.
    Jacobson, M.
    Jones, A.
    Tabuteau, H.
    [J]. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2019, 29 : S410 - S410
  • [6] Efficacy and Safety of AXS-05, an Oral, NMDA Receptor Antagonist with Multimodal Activity in Major Depressive Disorder: Results from the ASCEND Phase 2, Double-Blind, Active-Controlled Trial
    Jones, Amanda
    O'Gorman, Cedric
    Jacobson, Mark
    Iosifescu, Dan V.
    Tabuteau, Herriot
    [J]. NEUROTHERAPEUTICS, 2021, 18 (03) : 2138 - 2139
  • [7] Efficacy and Safety of AXS-05, an Oral NMDA Receptor Antagonist With Multimodal Activity, in Major Depressive Disorder: Results From the GEMINI Trial
    Jones, Amanda
    O'Gorman, Cedric
    Streicher, Caroline
    Feliz, Samantha
    Iosifescu, Dan V.
    Tabuteau, Herriot
    [J]. ANNALS OF CLINICAL PSYCHIATRY, 2021, 33 (03) : 15 - 15
  • [8] Efficacy and Safety of AXS-05, an Oral NMDA Receptor Antagonist, in the Prevention of Relapse in Patients With Treatment-Resistant Depression: Results From MERIT, a Double-Blind, Placebo-Controlled Relapse Prevention Trial
    Jones, Amanda
    O'Gorman, Cedric
    Anderson, Ashley
    Tabuteau, Herriot
    [J]. NEUROPSYCHOPHARMACOLOGY, 2021, 46 (SUPPL 1) : 201 - 201
  • [9] Efficacy and safety of aticaprant, a kappa receptor antagonist, adjunctive to oral SSRI/SNRI antidepressant in major depressive disorder: results of a phase 2 randomized, double-blind, placebo-controlled study
    Schmidt, Mark E.
    Kezic, Iva
    Popova, Vanina
    Melkote, Rama
    van der Ark, Peter
    Pemberton, Darrel J.
    Mareels, Guy
    Canuso, Carla M.
    Fava, Maurizio
    Drevets, Wayne C.
    [J]. NEUROPSYCHOPHARMACOLOGY, 2024, 49 (09) : 1437 - 1447
  • [10] Osmotic-release oral system methylphenidate augmentation of antidepressant monotherapy in major depressive disorder: Results of a double-blind, randomized, placebo-controlled trial
    Ravindran, Arun V.
    Kennedy, Sidney H.
    O'Donovan, M. Claire
    Fallu, Angelo
    Camacho, Fernando
    Binder, Carin E.
    [J]. JOURNAL OF CLINICAL PSYCHIATRY, 2008, 69 (01) : 87 - 94